There might be a drug that halts Alzheimer’s. Is an Alzheimer’s drug a good investment? The Alzheimer’s drug, aducanumab, has been given a new lease on life after a phase III trial was previously halted. Unlike other treatments for Alzheimer’s disease, aducanumab has the potential to halt the progression of the disease instead of just treating symptoms. The drug was discovered by Neurimmune and is licensed by Biogen Inc. The medical significance if this drug passes all trials and becomes available for treatment is great. But, is an Alzheimer’s drug a good investment?
https://youtu.be/pP2doNk59LI
*Navigating Electoral Terrain: TDP's Performance under N Chandrababu Naidu's ...
Is an Alzheimers Drug a Good Investment?
1. Is an Alzheimers Drug a Good
Investment?
By www.ProfitableInvestingTips.com
2. https://profitableinvestingtips.com/profitable-
investing-tips/is-a-alzheimers-drug-a-good-
investment
The Alzheimer’s drug, aducanumab, has been given a new
lease on life after a phase III trial was previously halted.
Unlike other treatments for Alzheimer’s disease,
aducanumab has the potential to halt the progression of
the disease instead of just treating symptoms. The drug
was discovered by Neurimmune and is licensed by
Biogen Inc. The medical significance if this drug passes
all trials and becomes available for treatment is great.
But, is an Alzheimer’s drug a good investment?
4. https://profitableinvestingtips.com/profitable-
investing-tips/is-a-alzheimers-drug-a-good-
investment
Aducanumab is a human monoclonal antibody. Unlike antibodies
that the body produces to fight infections, aducanumab targets
beta-amyloid which is the material that is found in the brains of
patients with Alzheimer’s disease. The plaques are toxic to nerve
cells in the brain. The rationale for aducanumab is that it can stop
the buildup of beta-amyloid and therefore the progression of
Alzheimer’s. The drug had progressed to a stage III FDA trial.
This means that it had been demonstrated not to cause any bad
side effects and that it helped in animal studies. In stage III the
goal is to prove that it has a statistically significant effect on the
progression of Alzheimer’s disease.
6. https://profitableinvestingtips.com/profitable-
investing-tips/is-a-alzheimers-drug-a-good-
investment
Stage III testing of this drug was halted in March of 2019
when it was believed that it would not meet expectations
and fail testing. However, re-evaluation of the study
results showed that it might work after all. Thus phase
III trials have been resumed. So far studies show that
patients taking a high dose of this drug have a 23%
reduction in their rate of decline from Alzheimer’s
disease. Now the FDA has indicated that the drug is safe
and effective which will clear the way for its FDA
approval as a treatment for Alzheimer’s.
8. https://profitableinvestingtips.com/profitable-
investing-tips/is-a-alzheimers-drug-a-good-
investment
The Mayo Clinic website lists four drugs currently available
to manage symptoms of Alzheimer’s. Three
cholinesterase inhibitors that help symptoms in mild to
moderate disease are Donepezil (Aricept), Galantamine
(Razadyne) and Rivastigmine (Exelon). These drugs help
until the reduction in viable brain tissue reduces the
amount of cholinesterase to inhibit. The other drug
which is used on more severe stages of the disease is
Memantine (Namenda). This drug also helps symptoms
but does nothing to slow the progression of or cure the
disease.
12. https://profitableinvestingtips.com/profitable-
investing-tips/is-a-alzheimers-drug-a-good-
investment
The current incidence of Alzheimer’s in people aged 65
and older is 10%. As the number of people in the older
age group increases so will the number of people
suffering from Alzheimer’s. Treatment of Alzheimer’s
will be for the rest of the person’s life and so long as the
medication helps. Thus treatment with aducanumab
could be for decades. This would be a significant income
stream for a company like Biogen.
14. https://profitableinvestingtips.com/profitable-
investing-tips/is-a-alzheimers-drug-a-good-
investment
Biogen is an American multinational biotech company that currently
trades for $324 a share on NASDAQ. Its primary focus is
treatments for neurological diseases but the company has many
other types of drugs. Their current list of drugs includes
treatments for multiple sclerosis, chronic lymphocytic leukemia,
spinal muscular atrophy, psoriasis, hemophilia A, and hemophilia
B. Drugs in development by Biogen include treatments for acute
optic neurites, lupus nephritis, idiopathic pulmonary fibrosis,
neuropathic pain, and amyotrophic lateral sclerosis (Lou Gehrig’s
Disease) along with aducanumab.
15. https://profitableinvestingtips.com/profitable-
investing-tips/is-a-alzheimers-drug-a-good-
investment
Biogen stock has had a very bumpy ride over the last seven
years as investors have alternately loved and hated the
stock due to the success or failure of its drugs in clinical
trials. While it currently sells for $330 a share the price
has been as high as $380 a share in 2015 and as low as
$234 a share in 2019. Investors who got in by 2000 saw
the stock go from $40 a share to its current price. The
stock has a P/E ratio of 10.98, does not pay a dividend,
and would see a nice addition to its income stream if
aducanumab becomes a mainstay for Alzheimer’s
treatment.